ejpmr, 2024, 11(7), 672-679

SJIF Impact Factor 7.065

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

THERAPEUTIC MANAGEMENT OFMALIGNANT HYPERTHERMIA: A COMPREHENSIVE REVIEW

Satish S., Sandra Thattiott* and A. R. Shabaraya

Department of Pharmacy Practice, Srinivas College of Pharmacy, Valachil, Post Farangipete, Mangalore-574143.

***Corresponding Author: Sandra Thattiott**

Department of Pharmacy Practice, Srinivas College of Pharmacy, Valachil, Post Farangipete, Mangalore-574143.

Article Received on 28/05/2024 **Article Revised on 18/06/2024** **Article Accepted on 08/07/2024**

ABSTRACT

Background: Malignant hyperthermia (MH) is a rare, life-threatening pharmacogenetic disordertypically triggered by certain anesthetic agents and muscle relaxants. It is characterized by rapid onset of hypermetabolic crisis, leading to severe hyperthermia, acidosis, muscle rigidity, and rhabdomyolysis. Prompt recognition and treatment are crucial to reduce morbidity and mortality. **Objective:** This review aims to provide a comprehensive overview of the therapeutic managementof MH, including the pathophysiology, early recognition, and latest advancements in treatment protocols. **Methods:** A thorough literature search was conducted using databases such as PubMed, MEDLINE, and Cochrane Library, focusing on publications from the last two decades. Key searchterms included "malignant hyperthermia," "treatment," "management," "dantrolene," and "anesthesia complications." Articles were selected based on relevance, quality, and contributions to current knowledge on MH management. **Results:** The review highlights the critical role of early diagnosis, the use of dantrolene as the primary pharmacological intervention, and supportive measures to manage complications. Key findings include: 1) Early Recognition and Diagnosis: Identifying early signs such as hypercapnia, tachycardia, and muscle rigidity is crucial. Genetic testing and caffeine-halothane contracture tests remain gold standards for diagnosis. 2) Pharmacological Management: Dantrolene remains the cornerstone of MH treatment, with recommendations for its administration and dosing regimens. New formulations of dantrolene have improved ease of use and response times. 3) Supportive Care: Managing hyperthermia, acidosis, and electrolyte imbalances through cooling measures, intravenous fluids, and bicarbonate therapy is essential. 4) Preventive Strategies: Genetic counseling and preoperative screening for high-risk individuals are critical for preventing MH episodes. Safe anesthesia practices, including the avoidance of triggering agents, are emphasized. **Conclusion:** The management of MH requires a multifaceted approach involving prompt identification, immediate administration of dantrolene, and comprehensive supportive care. Advances in pharmacological treatments and preventive strategies have significantly improved patient outcomes. Ongoing research and education are necessary to further enhance therapeutic protocols and reduce the incidence of MH-related complications.

KEYWORDS: Malignant hyperthermia, Dantrolene, Anesthesia, Pharmacogenetics, Hyperthermia management, Supportive care, Preoperative screening.

INTRODUCTION

Malignant hyperthermia is defined in the International Classification of Diseases as a "progressive life-threatening hyperthermic reaction occurring during general anaesthesia". A pharmacogenetic disorder of the skeletal muscle, malignant hyperthermia (MH) manifests as a hypermetabolic reaction to strong volatile anesthetic gases such as halothane, sevoflurane, desflurane, isoflurane, and the depolarizing muscle relaxant succinylcholine and in rare cases, to stressors such as heat, strenuous exercise. Anesthetics have a 1:10,000–1:250,000 incidence of MH responses. In light of the current understanding of the structure and function of the skeletal muscle calcium channel, this review highlights current diagnostic, management, and therapy approaches for the rare hereditary condition malignant hyperthermia.[2] This review seeks to give physicians the knowledge they need to successfully identify, prevent, and treat this potentially fatal disorder by exploring the most recent developments and debates in mental health research and clinical practice. MH, which is characterized by a dysregulated metabolism of skeletal muscle in response to specific anesthetic drugs, necessitates constant monitoring and prompt action from medical professionals. Although rare, the potentially catastrophic consequences mean that therapists need to be well-versed in MH. With regard to MH, this thorough study aims to provide light on the disease's complex

epidemiology, underlying pathophysiology, clinical presentation, diagnostic methods, and evidence-based therapy approaches. This study seeks to act as a knowledge illumination by combining the most recent research findings and clinical standards. This will enable healthcare workers to confidently and precisely traverse the complexity of mental health, thereby protecting patient well-being during the perioperative period.

Epidemiology of malignant hyperthermia

A. Prevalence and Incidence rates

Few cases of malignant hyperthermia (MH) have been documented in the literature, indicating the low frequency of this rare genetic condition in India.[2] When standard care is given, the estimated total incidence of mental illness during general anesthesia ranges from 1:5000 to 1:50,000-100,000, with a death rate of less than 5%.[3] Although MH is uncommon in India, there have been reported cases, including a 9-year-old kid slated for a craniotomy and a 22-year-old female receiving emergency laparoscopic surgery who both experienced probable MH episodes during anesthesia.[4][5] Confirmation and management of the condition are complicated by the unavailability of diagnostic procedures such as the in vitro halothane-caffeine contraction test and the restricted availability of the antidote dantrolene in the Indian market.

Improving outcomes for Mental Health (MH) patients in India requires early discovery, effective intervention, and increasing awareness among healthcare providers. With incidence rates ranging from 1:10,000 to 1:250,000, malignant hyperthermia (MH) is an uncommon pharmacogenetic illness marked by a hypermetabolic reaction to specific anesthetics and stressors.[7] [8] Similar to Western nations, the incidence of mental health illness (MH) in the Asian population, especially in China and Japan, has been found to be between one and two per 100,000 anesthetics.[9] All things considered, MH is an uncommon illness with a 9.5% death rate that affects people who are exposed to particular triggers; early detection and treatment are essential for a good prognosis.[10]

B. Genetic Predisposition and Familial incidence

Genetic predisposition to malignant hyperthermia (MH) involves an autosomal dominant inheritance in humans primarily linked to mutations in the RYR1 gene.[7] MH susceptibility is associated with specific genetic variants, such as p.Arg614Cys, leading to a hypermetabolic response triggered by an uncontrolled surge in myoplasmic calcium.[11] Whole exome sequencing(WES) has proven effective in identifying pathogenic alleles in MH families, even when the specimen of the suspected case is unavailable, highlighting the importance of genetic testing and counseling in families with a history of MH.[12] Furthermore, carriers of pathogenic RYR1 sequence variants show a tendency towards lower BMI values, suggesting a potential protective effect against obesity.[13] Early diagnosis through genetic testing and awareness of familial incidence are crucial in managing MH cases and reducing associated morbidity and mortality rates.

Pathophysiology of malignant hyperthermia

A. Genetic basis: Mutations in the ryanodine receptor (RYR1) Gene and Others

The primary cause of malignant hyperthermia (MH) is believed to be mutations in the ryanodine receptor type 1 (RYR1) gene, which is essential for maintaining calcium homeostasis in the skeletal muscle.[14][15] When these mutations are exposed to triggers such as volatile anesthetics, they cause aberrant release of calcium through the RyR1 channels, which in turn causes excessive production of heat.[16] p.Thr2206Met and p.Gly2434Arg, two of the detected RYR1 variants, have been linked to tubular aggregation myopathy and MH susceptibility, broadening the range of histological changes linked to RYR1 gene mutations.[17] Furthermore, several genes including as MYH1, TNNT3, MYLPF, and ATP2A1 were found to be possible biomarkers for the diagnosis of RYR1 mutation-associated myopathies by Wang et al.'s study, offering insights into the transcriptome-level mechanisms underlying the condition. These resultsemphasize that MH has a genetic foundation.

B. Mechanism of action: Abnormal calcium Handling and Skeletal muscle hypermetabolism

Abnormal calcium handling and skeletal muscle hypermetabolism are the characteristics of malignant hyperthermia (MH), which is brought on by a combination of genetic predisposition and specific anesthetics. Even in the absence of triggering agents, MH-susceptible individuals display impaired biochemical pathways. Metabolomic profiling indicates a shift towards lipid utilization for energy production, which may result in inefficient beta-oxidation, increased muscle protein turnover, oxidative stress, and elevated levels of lysophosphatidylcholine. Gene variants influencing RYR1 activity and calcium homeostasis, such as CASQ1 and RYR1, contribute to MH vulnerability by causing a hypermetabolic response that manifests as acidosis, hyperthermia, and muscle rigidity. Comprehending the molecular pathways that underlie the disrupted management of calcium in MH tissues offers valuable perspectives for the development of innovative treatmentsand further research directions.

C. Triggers and Onset of MH episodes

In addition to physical exertion combined with a febrile condition, exposure to strong inhalational anesthetics and depolarizing skeletal muscle relaxants can also cause bouts of malignant hyperthermia (MH). When volatile inhaled anesthetics and succinylcholine are combined, susceptible people—particularly those with abnormalities in the ryanodine receptor (RYR1) gene—are vulnerable to severe hypermetabolic states.[18][19] Early symptoms of MH episodes include tachycardia, hypercarbia, and muscle rigidity. Later symptoms

include severe acidosis, rhabdomyolysis, electrolyte abnormalities, and hyperthermia.[20] Early detection of these signs is essential for starting dantrolene therapy, the primary antidote for MH, to prevent morbidity and mortality.

Clinical Manifestations and Diagnosis

A. Signs and Symptoms of MH

A variety of signs and symptoms suggestive of a hypermetabolic condition brought on by exposure to volatile anesthetics and succinylcholine are present in malignant hyperthermia (MH). Muscle rigidity, hypercarbia, and tachycardia are among the initial clinical symptoms. These are followed by severe acidosis, rhabdomyolysis, hyperthermia, and abnormal electrolyte levels. Other symptoms include hyperkalemia, acidosis, tachypnea, elevated carbon dioxide generation, and rigidity in the muscles. Due to the syndrome's sensitivity or quick progression, diagnosis can be difficult, which can cause treatment delays and higher mortality.[7]

B. Diagnostic Criteria and Tools: Contracture testing, Genetic Testing and Others

Genetic testing and contracture testing are the two main methods used to diagnose malignant hyperthermia (MH). Muscle biopsy is necessary for contracture testing, namely the in vitro contracture test (IVCT), which uses halothane, caffeine, and occasionally ryanodine to diagnose MH susceptibility. Confirming MH susceptibility by this test is essential, particularly when genetic testing is negative for MH-related mutations.[20][21] In order to establish the existence of diagnostic MH mutations, genetic testing can be carried out in those with a high pretest risk of MH. Genetic testing is important in finding familial MH mutations.[22] Contracture testing is still necessary to rule out MH susceptibility, but genetic testing enhances the diagnosis by revealing certain mutations connected to MH and offers insightful information on the genetic basis of this pharmacogenetic disorder.

C. Differential diagnosis: Distinguishing MH from other causes of Hyperthermia and Muscle rigidity

Malignant hyperthermia (MH) is distinguished by specific clinical manifestations that set it apart from other causes of hyperthermia and muscle rigidity. Typical symptoms of MH comprise hyperthermia, tachycardia, tachypnea, increased carbon dioxide production, acidosis, hyperkalemia, muscular rigidity, and rhabdomyolysis, all suggestive of a hypermetabolic response.[7] Initial indications may encompass muscle stiffness, hypercarbia, and tachycardia, evolving into electrolyte irregularities, severe acidosis, and rhabdomyolysis. Moreover, dyspnea, hypotension, and elevated serum myoglobin may be apparent, underscoring the significance of identifying unusual clinical symptoms for timely diagnosis and management. Adequate preoperative evaluation and the utilization of the caffeine-halothane contracture test for diagnosis are pivotal in suspected instances of MH.[23] Additionally, individuals with MH susceptibility frequently display halothane hypersensitivity, .along with anomalous calcium events in muscle and musculoskeletal symptoms at rest.[24]

Management and Treatment strategies

A. Acute management: Immediate interventions in suspected MH crises

In the acute management of suspected malignant hyperthermia (MH), it is imperative to promptly implement interventions to avert life-threatening complications. Utilization of clinical presentation and end-tidal capnography, which demonstrates an elevation in end-tidal CO2 levels, serves as crucial diagnostic modalities.[25] The timely identification of signs indicative of an MH crisis, such as hyperthermia, muscle rigidity, and metabolic acidosis, is of paramount importance.[26] Therapeutic measures should encompass discontinuing triggering agents, administering dantrolene to impede intracellular calcium release, and addressing metabolic disturbances.[27][28] The timely initiation of the MH protocol, which includes dantrolene administration, is indispensable for achieving patient stabilization and favorable outcomes. Timely and suitable healthcare, informed by a heightened level of suspicion and clinical evaluation, can have a substantial effect on the survival of patients experiencing suspected MH crises.

B. Pharmacological treatments: role of Dantrolene and Other medications

Dantrolene plays a critical role as a pharmacological intervention for malignant hyperthermia (MH) by blocking abnormal Ca2+ release from the sarcoplasmic reticulum through its direct interaction with the skeletal ryanodine receptor (RyR1).[29] This medication is the primary choice in managing MH crises, effectively alleviating symptoms of increased metabolism such as elevated body temperature, muscle stiffness, and metabolic acidosis. Studies have demonstrated that dantrolene's inhibitory properties remain consistent regardless of the presence of RyR1 mutations, leading to a rise in the half-maximal effective concentration (EC50) for caffeine and a reduction in resting intracellular Ca2+ levels (Ca2+]i) among individuals predisposed to MH, with or without these genetic variations.[30][31] Furthermore, investigations have delved into the pharmacokinetics of dantrolene in the context of plasma exchange therapy, suggesting minimal adjustments in dosage requirements for MH-affected adolescents undergoing this particular treatment.[32]

C. Supportive measures: Temperature Control, Fluid Management, and Hemodynamic Support

Supportive interventions for malignant hyperthermia (MH) encompass measures such as regulating body temperature, managing fluids, and providing hemodynamic support to optimize patient results. The control of body temperature is paramount in the management of MH-induced hyperthermia, a condition that can swiftly escalate and result in serious

complications.[33] The management of fluids is crucial for upholding hemodynamic stability and ensuring adequate perfusion of the graft during MH episodes, particularly in pediatric patients with existing electrolyte and acid-base imbalances.[34] Moreover, the provision of hemodynamic support through careful administration of inotropic agents is indispensable for maintaining steady hemodynamics and graft function while addressing MH.[25] These supportive interventions, combined with prompt administration of dantrolene, are essential in the management of MH and in averting negative outcomes for affected individuals.[35][36] Collaborative teamwork and adherence to standardized protocols further improve patient safety and effectiveness during MH emergencies.

D. Anesthetic considerations for MH-Susceptible patients

For individuals at risk of Malignant Hyperthermia (MH), it is essential to consider alternative anesthetic methods and medications to minimize the possibility of inducing this potentially deadly condition. One strategy involves the utilization of total intravenous anesthesia with an alpha 2-agonist infusion in conjunction with epidurally administered bupivacaine. This combination can enhance intraoperative hemodynamic control and decrease the overall amount of intravenous anesthetics, such as propofol, thereby potentially preventing propofol infusion syndrome. Furthermore, incorporating activated charcoal filters like the Vapor-Clean device into the breathing circuit of the anesthesia machine can rapidly decrease anesthetic vapor levels to below 5 ppm, aiding in the prevention of MH reactions in vulnerable individuals.[37] It is also advisable to avoid specific inhalation agents like sevoflurane in patients with Duchenne's muscular dystrophy (DMD) to reduce the risk of complications such as rhabdomyolysis, a concern observed in documented cases linked to various inhaled anesthetics.[38]

E. Long-Term Management and Follow-Up

The enduring management and surveillance of malignant hyperthermia (MH) encompass pivotal measures to safeguard patient welfare and safety. Individuals predisposed to MH should undergo anesthesia devoid of provoking agents, with prophylactic dantrolene administration avoided and perioperative care remaining unchanged.[39] Routine follow-up consultations with an anesthesiologist are imperative to monitor for potential triggers or complications, particularly preceding any forthcoming surgical interventions.[25] Furthermore, specialized diagnostic methodologies such as the caffeine-halothane contracture test may be employed in non-acute scenarios to validate suspected MH cases.[40]

Complications and Prognosis

A. Complications Associated with MH Crisis

Complications linked to a crisis of malignant hyperthermia involve hypermetabolism of striated voluntary muscle, heightened oxygen consumption, lactate accumulation, CO2 production, excessive heat production, muscle rigidity, metabolic acidosis, dysrhythmias, cardiovascular changes, renal failure, and potential fatality if not swiftly managed with dantrolene.[41][42][43] Furthermore, individuals may encounter muscle issues in their everyday lives, like myalgia, cramps, or intolerance to physical activity.[44] In a documented case, the complexities of malignant hyperthermia in a pediatric patient undergoing ambulatory surgery comprised of hypothermia and thrombophlebitis, underscoring the significance of teamwork and adherence to standardized checklists for patient safety and effective crisis resolution. Timely recognition of signs and symptoms, coupled with prompt intervention, is paramount to ensuring a high survival rate in patients prone to malignant hyperthermia.

B. Long-Term Effects on Muscular and Organ Function

Malignant hyperthermia (MH) is associated with enduring impacts on both muscular and organ functionality. Studies have shown that MH can trigger persistent musculoskeletal issues like muscle soreness, spasms, weakness, and back/joint discomfort, along with psychological challenges such as depression and anxiety.[44] Moreover, MH can lead to sudden rhabdomyolysis, marked by a swift rise in body temperature and heightened levels of creatine kinase and myoglobin, thereby negatively affecting muscle performance.[45] Additionally, individuals predisposed to MH may endure ongoing muscle spasms and pain, which can restrict daily functions and disrupt sleep patterns; nevertheless, the administration of low-dose dantrolene demonstrates potential in easing these symptoms without causing harm to the liver.[46] These results emphasize the necessity of comprehending and addressing the enduring consequences of MH on muscular and organ function in order to enhance patient outcomes and overall quality of life.

C. Prevention strategies: preoperative screening, identification of MH-susceptible patients, and patient education

Susceptibility to malignant hyperthermia (MH) in patients is predominantly determined through the caffeine-halothane contracture test (CHCT), which entails assessing muscle reaction to halothane and caffeine.[47] This particular examination is widely regarded as the benchmark for diagnosing MH; however, it is intricate, expensive, and invasive, necessitating a significant quantity of muscle tissue and specialized equipment.[48] Genetic analysis is also employed to pinpoint MH susceptibility, concentrating on distinct genetic variations such as those found in the RYR1 gene.[49] Individuals with MH susceptibility may display symptoms like myalgia, cramps, and reduced tolerance to physical activity. Accurate diagnosis of MH is vital to ensure timely and appropriate intervention, typically involving the administration of dantrolene during an MH crisis. Further investigation is imperative to establish a connection between genetic discoveries and clinical

manifestations, thereby enhancing the comprehension and management of MH susceptibility.

Recent Advances and Research directions

A. Updates in understanding genetic mutations

Recent studies have illuminated the genetic mutations linked to malignant hyperthermia (MH), a rare pharmacogenetic condition induced by volatile anesthetics. Research has indicated that mutations in intracellular Ca2+ release channels, such as the RyR1-p R163C mutation, have the potential to interfere with Ca2+ signaling in skeletal muscle, thus contributing to susceptibility to MH in individuals.[50] Moreover, progress in genetic screening methodologies such as next- generation sequencing has facilitated the recognition of different RYR1 variations correlated with MH, leading to an enhanced comprehension of the relationship between genotype and phenotype as well as the varying penetrance of the disorder.[51][52]

B. Emerging Treatments and Therapies under investigation

Novel treatments and therapies currently being researched in malignant hyperthermia comprise hyperthermia therapy (HTT) combined with immunotherapy, nanomaterial-based photothermal therapy (PTT), and magnetic hyperthermia (MHT).[53] The utilization of whole-body hyperthermia (WBHT) is being investigated as a supplementary approach for disseminated malignancies, augmenting the efficacy of radiation and chemotherapy through its impact on the tumor microenvironment and cellular responsiveness to treatment [54] Moreover, innovative engineering strategies are being developed, utilizing nanoparticles and electromagnetic waves to attain optimal thermal effects for the treatment of malignant tumors, particularly metastases, in animal studies.[55]

Summary of key points on MH

Malignant hyperthermia (MH) is a rare pharmacogenetic disorder induced due to potent volatile anesthetics and stressors, with differential reaction rates but a high incidence of genetic anomalies.[6] It is evident as a hypermetabolic reaction with symptoms such as hyperthermia, tachycardia, and muscle rigidity, eventually leading to a fatal outcome if not attended. The condition is primarily autosomal dominant in humans, caused due to mutations in the ryanodine receptor gene.[25] primory diagnosis is paramount, with end-tidal carbon dioxide monitoring being a key indicator. Treatment implies dantrolene administration, along with controlling metabolic imbalances and close monitoring for recurrence. The mortality rate has remarkably decreased in the course of time due to enhanced understanding and management of the disease.

CONCLUSION

The management of malignant hyperthermia (MH) necessitates a swift, coordinated approach to mitigate its potentially fatal outcomes. This comprehensive review underscores the importance of early recognition and rapid intervention, which are critical for improving survival rates and reducing complications. Dantrolene remains the cornerstone of pharmacological treatment, with its timely administration being paramount. The evolution of dantrolene formulations has enhanced response efficiency, significantly contributing to better patient outcomes.

Supportive care measures, including aggressive cooling, correction of metabolic imbalances, and vigilant monitoring, are integral to the therapeutic protocol. Preventive strategies, such as genetic screening and the careful selection of anesthetic agents, play a crucial role in mitigating the risk of MH episodes. The emphasis on education and preparedness among healthcare professionals cannot be overstated, as it is essential for the effective management of this rare but critical condition.

Future research should focus on improving diagnostic methods, refining treatment protocols, and exploring novel therapeutic agents. Enhanced awareness and understanding of MH among medical practitioners and the general public will further aid in the timely and effective management of this condition, ultimately leading to improved patient safety and care.

REFERENCE

1. Rosenberg, H., Pollock, N., Schiemann, A. *et al.* Malignant hyperthermia: a review. *Orphanet J Rare Dis*, 2015; 10: 93.
2. Jaime, Elizabeth, Jose, L., R.., Di, Pace, José., Tisha, Ann, Babu., E.M., Hameeda. Malignant Hyperthermia Following Succinylcholine Administration: A Case Report. International journal of pharmaceutical sciences review and research, 2022; 4-7.
3. Asif, Iqbal, Shoaib, Badoo, Ruqsana, Naqeeb. A case report of suspected malignant hyperthermia where patient survived the episode. Saudi Journal of Anaesthesia, 2017; 11(2): 232-235.
4. Somrita, Laha, Prabhas, Prasun, Giri, Agnisekhar, Saha, Partha, P, Gupta, Anisha, De. Life-threatening Episodes of Malignant Hyperthermia Following Halothane Anesthesia in Three Children: A Case Series and Review of Literature, 2019; 23(1): 47-50.
5. C., V., Gopalakrishnan, B., Suparna., V., Arun. A rare case of malignant hyperthermia in the Indian subcontinent. Anaesthesia, 2010; 65(11): 1141-1142.
6. Pooja, Mathur, M, Rundla, Neena, Jain, Veena, Mathur. Malignant hyperthermia in a 6- month-old infant. Saudi Journal of Anaesthesia, 2016; 10(3): 353-355.
7. Priyanka, Tanwar., Mamta, Naagar., Garima, Malik., Md, Shamshir, Alam., Tarun, Singh., Omveer, Singh., Manish, Kumar, Maity. A review on Malignant Hyperthermia: Epidemiology, etiology, risk factors, diagnosis, clinical management and

treatment modalities. World Journal of Biology Pharmacy and Health Sciences, 2023; 13(1): 138- 168.
8. Fayziyev, Abdusamad, Abduxoliq, o`g`li., Stuti, Banerjee. Suspected malignant hyperthermia in a young Chinese patient undergoing a micro varicocelectomy surgery. Chinese Medical Journal, 2023. Publish Ahead of Print
9. Muhammad, Imran, Amjad, Hayat, Khan, Yaseen, Hussain, Fazlullah, Khan. A spectrumof severity and prevalence of malignant hyperthermia in anesthetized patients with inhalational anesthetic. Journal of Shifa Tameer-e-Millat University, 2023.
10. Mara, Sousa, Rita, Peixoto., Rui, Silva., Luísa, Guedes. Malignant Hyperthermia: A Case Report, 2020; 29(1): 27-29.
11. Gauze, Kitirattarkarn. Molecular Genetic Diagnosis of Human Malignant Hyperthermia, 2022; 293-317.
12. Asensio, Gonzalez, Thierry, Girard, Salome, Dell-Kuster., Albert, Urwyler., Oliver, Bandschapp. BMI and malignant hyperthermia pathogenic ryanodine receptor type 1 sequence variants in Switzerland: A retrospective cohort analysis. European Journal of Anaesthesiology, 2021; 38(7): 751-757.
13. Whole Exome Sequencing Revealing RYR1 Pathogenic Variant in an Exceptional Family with Malignant Hyperthermia Susceptibility. JOURNAL OF THE MEDICAL ASSOCTATION OF THAILAND, 2022; 105(1): 46-54.
14. Gaetano, Vattemi., Daniela, Rossi., Lucia, Galli., Maria, Rosaria, Catallo., Elia, Pancheri., Giulia, Marchetto., Barbara, Cisterna., Manuela, Malatesta., Enrico, Pierantozzi., Paolo, Tonin., Vincenzo, Sorrentino. Ryanodine receptor 1 (RYR1) mutations in two patients with tubular aggregate myopathy. European Journal of Neuroscience, 2022; 56(3): 4214-4223.
15. Xi, Wang, Chang, Kong., Pan, Liu., Wujun, Geng., Hongli, Tang. Identification of Potential Biomarkers for Ryanodine Receptor 1 (RYR1) Mutation-Associated Myopathies Using Bioinformatics Approach. Disease Markers, 2022; 2022: 1-11.
16. Ruth, White., Anja, H., Schiemann., S., M., Burling., Andrew, R., Bjorksten., Terasa, Bulger., R., L., Gillies., Philip, M., Hopkins., Erik-Jan, Kamsteeg., Roslyn, G., Machon., Sean, Massey., Dorota, M., Miller., Margaret, Perry., M., Snoeck., Jeremy, Stephens., Neil, E., Street., Luuk, R, van, den, Bersselaar., Kathryn, M., Stowell. Functional analysis of RYR1 variants in patients with confirmed susceptibility to malignant hyperthermia. BJA: British Journal of Anaesthesia, 2022; 129(6): 879-888.
17. Kotaro, Oyama., Vadim, Zeeb., Toshiko, Yamazawa., Nagomi, Kurebayashi., Fuyu, Kobirumaki-Shimozawa., Takashi, Murayama., Hideto, Oyamada., Satoru, Noguchi., Takayoshi, Inoue., Yukiko, Inoue., Ichizo, Nishino., Yoshie, Harada., Norio, Fukuda., Shin'ichi, Ishiwata., Madoka, Suzuki. Heat-hypersensitive mutants of ryanodine receptor type 1 revealed by microscopic heating. Proceedings of the National Academy of Sciences of the United States of America, 2022; 119(32).
18. Elena, Zvaritch, R., L., Gillies., Natalia, Kraeva., Maxime, Richer., Maxime, Richer., Heinz, Jungbluth., Heinz, Jungbluth., Heinz, Jungbluth., Sheila, Riazi. Fatal awake malignant hyperthermia episodes in a family with malignant hyperthermia susceptibility: a case series. Canadian Journal of Anaesthesia-journal Canadien D Anesthesie, 2019; 66(5): 540-545.
19. Antonio, Michelucci, Cecilia, Paolini., Simona, Boncompagni., Marta, Canato., Carlo, Reggiani., Feliciano, Protasi. Strenuous exercise triggers a life-threatening response in mice susceptible to malignant hyperthermia. The FASEB Journal, 2017; 31(8): 3649- 3662.
20. Thierry, Girard, Oliver, Bandschapp. Maligne Hyperthermie: Diagnostikkonkret. Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie, 2019; 54(09): 538-548.
21. Helga, Cristina, Almeida, da, Silva, Elton, Shinji, Onari., Isac, de, Castro., Marcelo, Vaz, Perez., Alexandre, Hortensi., José, Luiz, Gomes, do, Amaral. Anesthesia for muscle biopsyto test susceptibility to malignant hyperthermia. Revista Brasileira De Anestesiologia, 2019; 69(4): 335-341.
22. A, F, Dalmas, Nathalie, Roux-Buisson., F, Julien-Marsollier., C, Bosson., B, Bruneau., J, F, Payen., Julien, Fauré. Hyperthermiemaligne de l'anesthésie, 2019.
23. Qiao-Ling, Wang, Yu-Qing, Fang., Shuoguo, Jin., Jingtao, Liang., Yilin, Ren. Atypical symptoms of malignant hyperthermia: A rare causative mutation in the RYR1 gene. Open Medicine, 2022; 17(1): 239-244.
24. Lourdes, Figueroa, Natalia, Kraeva., Carlo, Manno., Carlos, A., Ibarra, Moreno., Eshwar, R, Tammineni., Sheila, Riazi., Eduardo, Ríos. Distinct pathophysiological characteristics in developing muscle from patients susceptible to malignant hyperthermia BJA: British Journal of Anaesthesia, 2023; 131(1): 47-55
25. M., A., Delgado. Malignant Hyperthermia: Clinical Management. International journal of medical science and clinical research studies, 2022; 02(10)
26. Fahad, Bahaidarah., Hassan, Gharamah, Mohammed, Alasmari., Ali, Adnan, Alkhamis., Ali, Ibrahim, Alshaqaqiq., Faisal, Abdulrahman, Hassan, Alasmari., Yousef, Abdulmohsen, Ali, Alrashed., Mahdi, Saleh, Alkhamis., Mohammad, Hassan, Alwadani., Aban, Wael, Alabbadi., Dhuha, Ali, Alshebli., Abdulmajeed, Abdulrhman, Alshahrani., Mohammed, Fahad, Al, Khalifah. Emergent Management of Malignant Hyperthermia: Review article, 2022; 3(1): 36-40.
27. Vendhan, Ramanujam, Christopher, Ryan,

Hoffman., Kevin, Russo., Michael, S., Green. Acute postoperative sepsis mimicking symptomology suspicious for malignant hyperthermia: case report. Revista Brasileira De Anestesiologia, 2019; 69(6): 622-625.
28. A., Kollmann-Camaiora., E., Alsina, Antonio, Domínguez., B., del, Blanco., M.J., Yepes., J., L., Guerrero., Angeles, García. Clinical protocol for the management of malignant hyperthermia. Revistaespañola de anestesiología y reanimación, 2017; 64(1): 32-40.
29. Jana, Gaburjakova., Marta, Gaburjakova. Molecular Aspects Implicated in Dantrolene Selectivity with Respect to Ryanodine Receptor Isoforms. International Journal of Molecular Sciences, 2023; 24(6): 5409-5409.
30. Xiaoxiao, Li., Chao, Li., Yang, Zhou, Zhengqian, Li., Xin, Xiong., Chuhui, Wang., Congya, Zhou., Bin, Han., Xian-rui, Guo. Pharmacokinetics of Dantrolene in the Plasma Exchange Treatment of Malignant Hyperthermia in a 14-Year-Old Chinese Boy: A Case Report and Literature Review. Frontiers in Medicine, 2022; 9
31. Yuko, Noda, Keiko, Mukaida., Hirotsugu, Miyoshi., K., Nakamura., Toshimichi, Yasuda.,Noboru, Saeki., Ichizo, Nishino., Yasuo, Tsutsumi. The effects of dantrolene in the presence or absence of ryanodine receptor type 1 variants in individuals predisposed to malignant hyperthermia. Anaesthesia and Intensive Care, 2022; 50: 312-319.
32. Wendy, Ingram. The effects of dantrolene in the presence or absence of ryanodine receptor type 1 variants in individuals predisposed to malignant hyperthermia. Anaesthesia and Intensive Care, 2022; 50(4): 312-319.
33. Sangeeth, P., Srinivasan, Nidhin, Eldo., Suresh, G, Nair. Malignant hyperthermia during pediatric kidney transplantation-A medical and ethical quandary. Pediatric Transplantation, 2021; 25(3).
34. A., Kollmann-Camaiora., E., Alsina., Antonio, Domínguez., B., del, Blanco., M.J., Yepes., J., L., Guerrero., Angeles, García. Clinical protocol for the management of malignant hyperthermia. Revistaespañola de anestesiología y reanimación, 2017; 64(1): 32-40.
35. Michael, A, Rubin, Stewart, J, Lustik, Camberly, I, Spring, Sonia, G, Pyne. Crisis Management in Malignant Hyperthermia, 2021; 12(4): 1-3.
36. Philip, M., Hopkins, Thierry, Girard, S., Dalay., Brian, J., Jenkins., A., J., Thacker., Mathew, V., Patteril., E., McGrady. Malignant hyperthermia 2020: Guideline from the Association of Anaesthetists. Anaesthesia, 2021; 76(5): 655-664.
37. David, S., Beebe, Vikram, Puram., Srdjan, Gajic., Bharat, Thyagarajan., Kumar, G., Belani. Genetics of malignant hyperthermia: A brief update. Journal of Anaesthesiology Clinical Pharmacology, 2020; 36(4): 552-555.
38. Alla, F., Fomina. Malignant hyperthermia and Alzheimer's disease causative mutations modulate calcium signaling in T lymphocytes. Physiology, 2023; 38(S1).
39. Fahad, Bahaidarah., Hassan, Gharamah, Mohammed, Alasmari., Ali, Adnan, Alkhamis., Ali, Ibrahim, Alshaqaqiq., Faisal, Abdulrahman, Hassan, Alasmari., Yousef, Abdulmohsen, Ali, Alrashed., Mahdi, Saleh, Alkhamis., Mohammad, Hassan, Alwadani., Aban, Wael, Alabbadi., Dhuha, Ali, Alshebli., Abdulmajeed, Abdulrhman, Alshahrani., Mohammed, Fahad, Al, Khalifah. Emergent Management of Malignant Hyperthermia: Review article, 2022; 3(1): 36-40.
40. F., Amiri., Mahbobe, Rashidi., M, Savaei. Malignant hyperthermia: A case report. Human pathology reports, 2023; 31: 300693-300693.
41. S., N., Ionov, M., V., Sharavina, Yu., S., Makhnycheva. Malignant Hyperthermia. Vestnikmedicinskogoinstituta "REAVIZ": reabilitaciâ, vračizdorov′e, 2022; 116, 4: P13-P15.
42. Michael, A, Rubin, Stewart, J, Lustik, Camberly, I, Spring, Sonia, G, Pyne. Crisis Management in Malignant Hyperthermia, 2021; 12(4): 1-3.
43. Wanderson, Penido, da, Costa, Thais, Morato, Menezes, Gláucio, Gregori, Nunes, Bomfá., Rodrigo, de, Lima, e, Souza., Paulo, Jacinto, Morato, Menezes., Lucas, Rodrigues, Motta. Malignant hyperthermia: reviewing important aspects, 2017; 27.
44. Shoshana, Burke, Menachem, Hanani. The actions of hyperthermia on the autonomic nervous system: central and peripheral mechanisms and clinical implications. Autonomic Neuroscience: Basic and Clinical, 2012; 168(1): 4-13.
45. S., N., Ionov., M., V., Sharavina., Yu., S., Makhnycheva. Malignant Hyperthermia. Vestnikmedicinskogoinstituta "REAVIZ": reabilitaciâ, vračizdorov′e, 2022; 116, 4: P13-P15.
46. Kristian, Werneid, Barbara, W., Brandom. Survey of Long-Term Sequelae in Survivors of a Malignant Hyperthermia Reaction. Open Journal of Anesthesiology, 2016; 06(1): 1-7.
47. Lourdes, Figueroa, Natalia, Kraeva., Carlo, Manno., Carlos, A., Ibarra, Moreno., Eshwar, R, Tammineni., Sheila, Riazi., Eduardo, Ríos. Distinct pathophysiological characteristics in developing muscle from patients susceptible to malignant hyperthermia. BJA: British Journal of Anaesthesia, 2023; 131(1): 47-55.
48. K., M., Yacob. New fever and hyperthermia diagnosing methods. World Journal of Advanced Research and Reviews, 2022; 16(2): 524-530.
49. Carlos, A., Ibarra, Moreno., Natalia, Kraeva., Elena, Zvaritch., Lourdes, Figueroa., Eduardo, Ríos., Leslie, G., Biesecker., Filip, Van, Petegem., Philip, M., Hopkins., Philip, M., Hopkins., Sheila, Riazi. A multi-dimensional analysis of genotype-phenotype discordance in malignant hyperthermia susceptibility. BJA: British Journal of Anaesthesia, 2020; 125(6): 995-1001.
50. David, S., Beebe, Vikram, Puram, Srdjan, Gajic,

Bharat, Thyagarajan., Kumar, G., Belani. Genetics of malignant hyperthermia: A brief update. Journal of Anaesthesiology Clinical Pharmacology, 2020; 36(4): 552-555.

51. Alla, F., Fomina. Malignant hyperthermia and Alzheimer's disease causative mutations modulate calcium signaling in T lymphocytes Physiology, 2023; 38(S1).
52. Young, Jae, Moon, Joon-Hee, Park, Jung, Ryul, Kim, Seung, Yeob, Lee., Jaehyeon, Lee., Yonggon, Cho., Dal, Sik, Kim. Gene Panel Sequencing Identifies a Novel RYR1 p.Ser2300Pro Variant as Candidate for Malignant Hyperthermia with Multi-Minicore Myopathy. Genes, 2022; 13(10): 1726-1726.
53. Fahad, Bahaidarah., Hassan, Gharamah, Mohammed, Alasmari., Ali, Adnan, Alkhamis., Ali, Ibrahim, Alshaqaqiq., Faisal, Abdulrahman, Hassan, Alasmari., Yousef, Abdulmohsen, Ali, Alrashed., Mahdi, Saleh, Alkhamis., Mohammad, Hassan, Alwadani., Aban, Wael, Alabbadi., Dhuha, Ali, Alshebli., Abdulmajeed, Abdulrhman, Alshahrani., Mohammed, Fahad, Al, Khalifah. Emergent Management of Malignant Hyperthermia: Review article, 2022; 3(1): 36-40.
54. Mengyu, Chang, Mengyu, Chang, Zhiyao, Hou., Zhiyao, Hou., Man, Wang., Chunxia, Li., Jun, Lin., Jun, Lin. Recent Advances in Hyperthermia Therapy-Based Synergistic Immunotherapy. Advanced Materials, 2021; 33(4): 2004788.
55. Ivana, Gorbaslieva., Dana, A, M, Mustafa., Robin, Colenbier., Marc, Peeters., Dirk, Ysebaert., Vera, Saldien., Luigi, Brancato., O., Rudenko., J., Van, den, Bossche., Jean, Paul, Bogers. Abstract A023: First in-human, safety and preliminary efficacy study of (neo) adjuvant, model-based, whole-body hyperthermia treatment in advanced solid cancerpatients or stage IV (TxNxM1) metastatic pancreatic adenocarcinoma patients: Liquid biopsies. Cancer Research, 2022; 82(22): A023-A023.